Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in France
Latest Information Update: 30 Nov 2022
At a glance
- Drugs Arimoclomol (Primary)
- Indications Niemann-Pick disease type C
- Focus Expanded access; Therapeutic Use
- 23 Sep 2022 According to a LadRx Corporation media release, CytRx Corporation has changed it's name to LadRx Corporation.
- 12 Mar 2021 New trial record